UCB
United States
48 articles with UCB
-
The rejection appears to be related to pre-approval inspection issues that need to be resolved before it can be approved.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
4/1/2022
UCB announced that new data from its expansive and innovative neurology portfolio will be presented at the 74th American Academy of Neurology Annual Meeting, from April 2-7, 2022.
-
UCB's oral drug for seizures related to Lennox-Gastaut syndrome is now approved in the U.S. for patients ages two years and older.
-
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
3/26/2022
UCB, a global biopharmaceutical company, announced that it is presenting 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology Annual Meeting in Boston, Massachusetts, U.S., on March 25-29, including a late breaking oral platform presentation and 10 posters.
-
BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases
3/8/2022
BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced a partnership with the global biopharmaceutical company, UCB, to develop and bring to market a digital disease management solution for patients with rare diseases.
-
It was a relatively quiet week for clinical trial announcements. Here’s a look.
-
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
2/4/2022
UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) trial.
-
UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.
-
Clinical Catch-Up: January 17-21
1/24/2022
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
UCB to acquire Zogenix
1/19/2022
Regulated information – Inside information – UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
-
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
12/10/2021
Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis (gMG).
-
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care
12/3/2021
UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the 75th American Epilepsy Society Annual Meeting (Chicago, Illinois), December 3-7, 2021.
-
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
12/2/2021
UCB announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson's Disease.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Her career as a physician and scientist is guided by a combination of logic and creativity.
-
UCB Showcases Key Rheumatology Data at ACR Convergence 2021
11/5/2021
UCB, a global biopharmaceutical company, announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF inhibitor, CIMZIA®.